Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...

Industry experts gathered at the Outsourcing in Clinical Trials East Coast 2025 conference to discuss artificial intelligence ...

Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin.

Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk MDS.

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...